[go: up one dir, main page]

NO20081884L - Modulasjon av glukagonreseptorekspresjon - Google Patents

Modulasjon av glukagonreseptorekspresjon

Info

Publication number
NO20081884L
NO20081884L NO20081884A NO20081884A NO20081884L NO 20081884 L NO20081884 L NO 20081884L NO 20081884 A NO20081884 A NO 20081884A NO 20081884 A NO20081884 A NO 20081884A NO 20081884 L NO20081884 L NO 20081884L
Authority
NO
Norway
Prior art keywords
glucagon receptor
modulation
receptor expression
compounds
expression
Prior art date
Application number
NO20081884A
Other languages
English (en)
Norwegian (no)
Inventor
Susan M Freier
Brett P Monia
Sanjay Bhanot
Original Assignee
Johnson & Johnson Pharm Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Pharm Res filed Critical Johnson & Johnson Pharm Res
Publication of NO20081884L publication Critical patent/NO20081884L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
NO20081884A 2005-09-19 2008-04-18 Modulasjon av glukagonreseptorekspresjon NO20081884L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71868405P 2005-09-19 2005-09-19
PCT/US2006/036545 WO2007035771A2 (fr) 2005-09-19 2006-09-19 Modulation de l'expression du recepteur du glucagon

Publications (1)

Publication Number Publication Date
NO20081884L true NO20081884L (no) 2008-06-12

Family

ID=37823390

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081884A NO20081884L (no) 2005-09-19 2008-04-18 Modulasjon av glukagonreseptorekspresjon

Country Status (16)

Country Link
US (1) US20070087987A1 (fr)
EP (3) EP2388326A1 (fr)
JP (1) JP2009508528A (fr)
KR (1) KR20080074101A (fr)
CN (1) CN101321869A (fr)
AT (1) ATE519845T1 (fr)
AU (1) AU2006292217A1 (fr)
BR (1) BRPI0616158A2 (fr)
CA (1) CA2623762A1 (fr)
CR (1) CR9907A (fr)
EA (1) EA200800869A1 (fr)
EC (1) ECSP088299A (fr)
ES (1) ES2369328T3 (fr)
NO (1) NO20081884L (fr)
WO (1) WO2007035771A2 (fr)
ZA (1) ZA200803453B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407943B2 (en) * 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US20060009410A1 (en) * 2002-11-13 2006-01-12 Crooke Rosanne M Effects of apolipoprotein B inhibition on gene expression profiles in animals
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7399853B2 (en) * 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
US7750142B2 (en) 2003-04-28 2010-07-06 Isis Pharmaceuticals, Inc. Modulation of glucagon receptor expression
US20050287558A1 (en) * 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
WO2007131237A2 (fr) * 2006-05-05 2007-11-15 Isis Pharmaceuticals, Inc. Composés et procédés permettant de moduler l'expression de la protéine ptp1b
KR20090128494A (ko) * 2007-03-24 2009-12-15 겐자임 코포레이션 인간 아포리포프로틴 ｂ에 상보적인 안티센스 올리고뉴클레오타이드 투여
EP2408796B1 (fr) 2009-03-16 2020-04-22 Ionis Pharmaceuticals, Inc. Ciblage de l'Apolipoprotéine B pour la réduction de l'apolipoprotéine C-III
CN101586103B (zh) * 2009-06-25 2010-12-08 上海交通大学 胰高血糖素受体基因的rna干扰序列
CN101851625B (zh) * 2009-06-25 2012-07-18 上海交通大学 胰高血糖素受体基因的rna干扰序列
CA2786568A1 (fr) * 2010-01-25 2011-07-28 Curna, Inc. Traitement de maladies liees a la rnase h1 par l'inhibition du produit de transcription naturel antisens de la rnase h1
ES2796556T3 (es) 2011-09-20 2020-11-27 Ionis Pharmaceuticals Inc Modulación antisentido de la expresión de GCGR
AP2015008674A0 (en) * 2013-04-22 2015-08-31 Cadila Healthcare Ltd A novel composition for nonalcoholic fatty liver disease (NAFLD)
SG11201508870VA (en) 2013-05-01 2015-11-27 Isis Pharmaceuticals Inc Compositions and methods for modulating hbv and ttr expression
CN104231083A (zh) * 2013-06-09 2014-12-24 杭州鸿运华宁生物医药工程有限公司 抗胰高血糖素受体的抗体及其用途
MX375446B (es) * 2013-07-02 2025-03-06 Ionis Pharmaceuticals Inc Moduladores de receptor de hormona de crecimiento.
KR20200102553A (ko) 2014-05-01 2020-08-31 아이오니스 파마수티컬즈, 인코포레이티드 성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
CN108026529A (zh) * 2015-09-30 2018-05-11 Ionis制药公司 组合疗法
US11400161B2 (en) 2016-10-06 2022-08-02 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
EP3752249A1 (fr) 2018-02-13 2020-12-23 Ligand Pharmaceuticals, Inc. Antagonistes de récepteur de glucagon

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
WO1988010264A1 (fr) 1987-06-24 1988-12-29 Howard Florey Institute Of Experimental Physiology Derives de nucleosides
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
ATE154246T1 (de) 1990-07-27 1997-06-15 Isis Pharmaceuticals Inc Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
AU1893192A (en) * 1991-03-28 1992-11-02 University Of Tennessee Research Corporation, The Dna silver staining
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
WO1993010820A1 (fr) 1991-11-26 1993-06-10 Gilead Sciences, Inc. Formation amelioree de triple et double helices a l'aide d'oligomeres contenant des pyrimidines modifiees
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
DE69333726T8 (de) * 1992-08-28 2006-04-27 Novo Nordisk A/S Glucagonrezeptoren
US5776725A (en) 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
AU6794594A (en) * 1993-04-30 1994-11-21 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta (tgf-beta )
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5646269A (en) 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US6028183A (en) 1997-11-07 2000-02-22 Gilead Sciences, Inc. Pyrimidine derivatives and oligonucleotides containing same
US6007992A (en) 1997-11-10 1999-12-28 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US20030228597A1 (en) * 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6492152B1 (en) * 1999-06-15 2002-12-10 The Board Of Regents Of The University Of Oklahoma Core 1 β3-galactosyl transferases and methods of use thereof
US6284538B1 (en) * 1999-07-21 2001-09-04 Isis Pharmaceuticals, Inc. Antisense inhibition of PTEN expression
US6909031B2 (en) * 2000-12-06 2005-06-21 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
WO2002097134A2 (fr) 2001-05-25 2002-12-05 Isis Pharmaceuticals, Inc. Acide nucleique peptide modifie
US20030158403A1 (en) 2001-07-03 2003-08-21 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US20030175906A1 (en) 2001-07-03 2003-09-18 Muthiah Manoharan Nuclease resistant chimeric oligonucleotides
US7399853B2 (en) * 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
US7750142B2 (en) 2003-04-28 2010-07-06 Isis Pharmaceuticals, Inc. Modulation of glucagon receptor expression
US7406521B2 (en) 2003-08-09 2008-07-29 Bohannon Gary P System and methods for controlled device access
US7825235B2 (en) * 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US20050074801A1 (en) * 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US20050053981A1 (en) * 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
AU2004303464B2 (en) * 2003-12-23 2009-10-01 Santaris Pharma A/S Oligomeric compounds for the modulation of BCL-2
JP2008513507A (ja) * 2004-09-17 2008-05-01 アイシス ファーマシューティカルズ インコーポレイティッド 増強されたアンチセンスオリゴヌクレオチド
WO2007131237A2 (fr) * 2006-05-05 2007-11-15 Isis Pharmaceuticals, Inc. Composés et procédés permettant de moduler l'expression de la protéine ptp1b

Also Published As

Publication number Publication date
AU2006292217A1 (en) 2007-03-29
ATE519845T1 (de) 2011-08-15
CA2623762A1 (fr) 2007-03-29
WO2007035771A2 (fr) 2007-03-29
EP2388326A1 (fr) 2011-11-23
JP2009508528A (ja) 2009-03-05
EP1937813A2 (fr) 2008-07-02
ECSP088299A (es) 2008-05-30
ZA200803453B (en) 2009-09-30
US20070087987A1 (en) 2007-04-19
CR9907A (es) 2009-01-16
EP2096170B1 (fr) 2011-08-10
EA200800869A1 (ru) 2008-10-30
WO2007035771A3 (fr) 2007-10-04
ES2369328T3 (es) 2011-11-29
CN101321869A (zh) 2008-12-10
KR20080074101A (ko) 2008-08-12
EP2096170A1 (fr) 2009-09-02
BRPI0616158A2 (pt) 2011-06-07

Similar Documents

Publication Publication Date Title
NO20081884L (no) Modulasjon av glukagonreseptorekspresjon
EA200800868A1 (ru) Модуляция экспрессии глюкокортикоидного рецептора
WO2009046141A3 (fr) Modulation antisens de l'expression du récepteur 4 du facteur de croissance des fibroblastes
CY1117030T1 (el) Τροποποιηση της εκφρασης απολιποπρωτεϊνης c-iii
WO2004096016A3 (fr) Modulation de l'expression du recepteur de glucagon
WO2005049630A3 (fr) Modulation antisens de l'expression de la proteine de type kinesine 1
WO2004071407A3 (fr) Modulation antisens de l'expression de ptp1b
WO2005005599A3 (fr) Modulation de l'expression de la proteine c-reactive
TW200519202A (en) Modulation of eIF4E expression
DE60143901D1 (de) Antisense-modulation der clusterinexpression
WO2004048534A3 (fr) Modulation de l'expression d'une kinase pouvant etre induite par une cytokine
WO2006026485A3 (fr) Modulation de l'expression de hif1 beta
WO2004096996A3 (fr) Modulation de l'expression du recepteur du glucagon
WO2005014607A3 (fr) Modulation antisens de l'expression de la stearoyl-coa desaturase
EP1248792A4 (fr) Modulation antisens de l'expression du recepteur gamma active de la proliferation des peroxysomes (ppar)
WO2009071680A3 (fr) Composés d'antagonistes d'arn utiles pour moduler mcl-1
WO2003104397A3 (fr) Modulation antisens de l'expression de la proteine kinase gr 6
WO2003050244A3 (fr) Modulation antisens de l'expression de recepteur etbr-lp-2 couple aux proteines g
WO2007062380A3 (fr) MODULATION DE L'EXPRESSION D’eIF4E-BP2
WO2005086804A3 (fr) Modulation de l'expression de ace2
WO2005006958A3 (fr) Modulation de l'expression de ceacam1
WO2004048524A3 (fr) Modulation de l'expression de stat2
WO2004011623A3 (fr) Modulation antisens de l'expression de la ptpra
WO2003099204A3 (fr) Modulation anti-sens de l'expression inhibiteur kappa b kinase-beta
WO2005007825A3 (fr) Modulation de l'expression de l'aminopeptidase n

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application